JP2018502068A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018502068A5 JP2018502068A5 JP2017530141A JP2017530141A JP2018502068A5 JP 2018502068 A5 JP2018502068 A5 JP 2018502068A5 JP 2017530141 A JP2017530141 A JP 2017530141A JP 2017530141 A JP2017530141 A JP 2017530141A JP 2018502068 A5 JP2018502068 A5 JP 2018502068A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- fusion protein
- condition
- high affinity
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462089097P | 2014-12-08 | 2014-12-08 | |
| US62/089,097 | 2014-12-08 | ||
| US201562200557P | 2015-08-03 | 2015-08-03 | |
| US62/200,557 | 2015-08-03 | ||
| PCT/US2015/064572 WO2016094456A1 (en) | 2014-12-08 | 2015-12-08 | Soluble universal adcc-enhancing synthetic fusion gene and peptide technology and its use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020198225A Division JP2021035994A (ja) | 2014-12-08 | 2020-11-30 | 可溶性ユニバーサルａｄｃｃ増強合成融合遺伝子およびペプチド技術ならびにその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018502068A JP2018502068A (ja) | 2018-01-25 |
| JP2018502068A5 true JP2018502068A5 (https=) | 2018-12-13 |
| JP7095992B2 JP7095992B2 (ja) | 2022-07-05 |
Family
ID=56108081
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017530141A Active JP7095992B2 (ja) | 2014-12-08 | 2015-12-08 | 可溶性ユニバーサルａｄｃｃ増強合成融合遺伝子およびペプチド技術ならびにその使用 |
| JP2020198225A Pending JP2021035994A (ja) | 2014-12-08 | 2020-11-30 | 可溶性ユニバーサルａｄｃｃ増強合成融合遺伝子およびペプチド技術ならびにその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020198225A Pending JP2021035994A (ja) | 2014-12-08 | 2020-11-30 | 可溶性ユニバーサルａｄｃｃ増強合成融合遺伝子およびペプチド技術ならびにその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12247062B2 (https=) |
| EP (1) | EP3230311B1 (https=) |
| JP (2) | JP7095992B2 (https=) |
| KR (1) | KR102654033B1 (https=) |
| CN (1) | CN107108718B (https=) |
| AU (1) | AU2015360642B2 (https=) |
| CA (1) | CA2968987C (https=) |
| NZ (1) | NZ732073A (https=) |
| RU (1) | RU2725807C2 (https=) |
| SG (1) | SG11201704124YA (https=) |
| WO (1) | WO2016094456A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201804945WA (en) | 2013-12-12 | 2018-07-30 | Shanghai hengrui pharmaceutical co ltd | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof |
| KR102654033B1 (ko) | 2014-12-08 | 2024-04-02 | 1글로브 바이오메디칼 씨오., 엘티디. | 가용성 유니버셜 adcc 증강 합성 융합 유전자 및 펩티드 기술 및 그 용도 |
| US12269863B2 (en) | 2018-05-23 | 2025-04-08 | Manysmart Therapeutics, Inc. | Bispecific T cell engager and uses thereof |
| WO2020232247A1 (en) | 2019-05-14 | 2020-11-19 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| IL298999A (en) | 2020-06-11 | 2023-02-01 | Provention Bio Inc | Methods and compositions for the prevention of type 1 diabetes |
| TW202216174A (zh) * | 2020-06-30 | 2022-05-01 | 日商蓋亞生物製藥有限公司 | 使ｎｋ細胞與抗體之結合穩定化之方法及其利用 |
| JP2024520444A (ja) | 2021-05-24 | 2024-05-24 | プロヴェンション・バイオ・インコーポレイテッド | １型糖尿病を治療するための方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223426A (en) * | 1988-12-15 | 1993-06-29 | T Cell Sciences, Inc. | Monoclonal antibodies reactive with defined regions of the t-cell antigen receptor |
| IE920716A1 (en) * | 1991-03-07 | 1992-09-09 | Gen Hospital Corp | Redirection of cellular immunity by receptor chimeras |
| EP0826696B1 (de) * | 1996-09-03 | 2002-05-29 | GSF-Forschungszentrum für Umwelt und Gesundheit GmbH | Verwendung bi-und trispezifischer Antikörper zur Induktion einer Tumorimmunität |
| PT1974747E (pt) * | 1998-08-11 | 2012-09-05 | Biogen Idec Inc | Terapias de combinação para linfomas de células b compreendendo a administração de anticorpo anti-cd20 |
| IL155812A0 (en) * | 2000-12-07 | 2003-12-23 | Lilly Co Eli | Glp-1 fusion proteins |
| WO2002098897A2 (en) * | 2001-06-01 | 2002-12-12 | Cornell Research Foundation, Inc. | Modified antibodies to prostate-specific membrane antigen and uses thereof |
| EP1597350B1 (en) * | 2003-02-27 | 2015-04-08 | Yeda Research And Development Co., Ltd. | Nucleic acid molecules, and compositions containing same useful for treating and detecting influenza virus infection |
| JP2006526414A (ja) | 2003-06-02 | 2006-11-24 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 脱免疫化抗ｃｄ３抗体 |
| MXPA06004035A (es) * | 2003-10-16 | 2006-08-31 | Micromet Ag | Aglutinantes cd3 de-inmunizados multi-especificos. |
| EP1716178B1 (en) * | 2004-02-16 | 2010-08-11 | Micromet AG | Less immunogenic binding molecules |
| US20080003225A1 (en) | 2006-06-29 | 2008-01-03 | Henri Vie | Method for enhancing the antibody-dependent cellular cytotoxicity (ADCC) and uses of T cells expressing CD16 receptors |
| AU2008209436A1 (en) * | 2007-01-23 | 2008-07-31 | Zymogenetics, Inc. | Soluble Fc gamma R1a for reducing inflammation |
| US8043621B2 (en) * | 2007-05-10 | 2011-10-25 | Ramot At Tel Aviv University Ltd. | Recombinant fusion protein and polynucleotide construct for immunotoxin production |
| WO2011085178A1 (en) | 2010-01-11 | 2011-07-14 | Trustees Of Dartmouth College | Monomeric bi-specific fusion protein |
| US9505826B2 (en) * | 2010-12-22 | 2016-11-29 | Teva Pharmaceuticals Australia Pty Ltd | Modified antibody with improved half-life |
| HK1202587A1 (en) * | 2011-12-15 | 2015-10-02 | The Royal Institution For The Advancement Of Learning/Mcgill University | Soluble igf receptor fc fusion proteins and uses thereof |
| MX353382B (es) * | 2012-03-01 | 2018-01-10 | Amgen Res Munich Gmbh | Moleculas de union polipeptido de larga duracion. |
| KR102654033B1 (ko) | 2014-12-08 | 2024-04-02 | 1글로브 바이오메디칼 씨오., 엘티디. | 가용성 유니버셜 adcc 증강 합성 융합 유전자 및 펩티드 기술 및 그 용도 |
-
2015
- 2015-12-08 KR KR1020177018958A patent/KR102654033B1/ko active Active
- 2015-12-08 CN CN201580064820.XA patent/CN107108718B/zh active Active
- 2015-12-08 WO PCT/US2015/064572 patent/WO2016094456A1/en not_active Ceased
- 2015-12-08 AU AU2015360642A patent/AU2015360642B2/en not_active Ceased
- 2015-12-08 RU RU2017124141A patent/RU2725807C2/ru active
- 2015-12-08 EP EP15867381.4A patent/EP3230311B1/en active Active
- 2015-12-08 SG SG11201704124YA patent/SG11201704124YA/en unknown
- 2015-12-08 US US15/532,770 patent/US12247062B2/en active Active
- 2015-12-08 CA CA2968987A patent/CA2968987C/en active Active
- 2015-12-08 JP JP2017530141A patent/JP7095992B2/ja active Active
- 2015-12-08 NZ NZ732073A patent/NZ732073A/en not_active IP Right Cessation
-
2020
- 2020-11-30 JP JP2020198225A patent/JP2021035994A/ja active Pending
-
2022
- 2022-04-12 US US17/719,194 patent/US20220235115A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113710707B (zh) | 结合于psma的重链抗体 | |
| JP2018502068A5 (https=) | ||
| JP7254699B2 (ja) | 抗ｂｃｍａ重鎖のみ抗体 | |
| JP7303126B2 (ja) | 抗ｂｃｍａ重鎖のみ抗体 | |
| Xu et al. | Retargeting T cells to GD2 pentasaccharide on human tumors using bispecific humanized antibody | |
| JP2021515566A5 (https=) | ||
| JP2021516976A5 (https=) | ||
| Getts et al. | Have we overestimated the benefit of human (ized) antibodies? | |
| JP2020525032A5 (https=) | ||
| JP2015163068A5 (https=) | ||
| JP2021516973A5 (https=) | ||
| JP2021533726A5 (https=) | ||
| JP2021515565A5 (https=) | ||
| JP2021516974A5 (https=) | ||
| JP2017532952A5 (https=) | ||
| JP2017529067A (ja) | Ｃｄ３結合ドメイン | |
| JP2016513467A5 (https=) | ||
| JP2018508483A5 (https=) | ||
| JP2011509245A5 (https=) | ||
| JP2021530207A (ja) | 二重特異性抗体及びその使用 | |
| JP2022505445A5 (https=) | ||
| JP2013520984A5 (https=) | ||
| RU2013106217A (ru) | Гибридный белок из антитела против мнс и противовирусного цитокина | |
| RU2017145662A (ru) | Моноклональные антитела и способы их применения | |
| WO2022242703A1 (zh) | 抗msln抗体及其应用 |